Citations

Clear

1434 citation(s) found for "Le, Nathan".

Idecabtagene vicleucel and endogenous T‐cell phenotypes linked to progression‐free survival in relapsed multiple myeloma
Paiva, Bruno , Manrique, Irene , Thompson, Ethan, CAMPBELL, TIMOTHY B., Guerrero, Camila, Martin, Nathan, Anderson, Larry D. , Lonial, Sagar, Raje, Noopur S., Lin, Yi, Moreau, Philippe, San-Miguel, Jesus, Munshi, Nikhil C., Kaiser, Shari, Paiva, Bruno , Anderson, Larry D , Thompson, Ethan G., Berdeja, Jesús G. , Lonial, Sagar , Moreau, Philippe , San-Miguel, Jesus , Munshi, Nikhil C.

Mayo Clinic

HemaSphere | July 2, 2026 | Volume: 10 | Issue: 7 | Pages: No page available

10.1002/hem3.70423 | PMID 42396130 Get It

Abstract Improved understanding of how chimeric antigen receptor (CAR) and endogenous T‐cell phenotypes associate with progression‐free survival (PFS) is needed to individualize and improve immunotherapy outcomes in multiple myeloma (MM). We characterized and investigated the prognostic value of immune dynamics defined with multidimensional and computational flow cytometry in 258 bone marrow aspirates from 107 MM patients treated with idecabtagene vicleucel in the KarMMa trial. At screening, there was an association between longer PFS and increased percentages of PD1 + cytotoxic T cells and ICOS − TIGIT + Tregs. At Month 1 after infusion, the presence of >1% CAR‐T cells, a CD4/CD8 CAR‐T‐cell ratio >0.09, and greater abundance of non‐activated non‐cytolytic CAR‐T cells identified patients with longer PFS. Notably, 47 of the 115 endogenous T‐cell clusters were prognostic at the latest assessment performed after CAR‐T infusion. Lower percentages of ICOS + TIGIT − Tregs showed the strongest association with longer PFS. Altogether, this large dataset of dynamic immune profiling throughout treatment with anti‐B‐cell maturation antigen (anti‐BCMA) CAR‐T cells uncovered that the T‐cell composition prior to apheresis as well as CAR‐T and endogenous T‐cell phenotypes after infusion associates with PFS. These findings have potential for translation into routine laboratory practice for improved understanding of response and resistance to CAR‐T cells in relapsed/refractory MM.
ID #759 Outcomes following focal proton therapy for non-metastatic intracranial atypical teratoid/rhabdoid tumor (ATRT)
Indelicato, Daniel, Mailhot-Vega, Raymond, Thompson, Elizabeth , Johnson, Bryan, Morris, Chris, Klawinski, Darren, Ranalli, Nathan, Bradley, J R, Vega, Raymond B. Mailhot , Mailhot Vega, Raymond B , Klawinski, Darren , Ranalli, Nathan J.

Mayo Clinic

Neuro-Oncology Pediatrics | June 24, 2026 | Volume: 2 | Issue: Supplement_1 | Pages: No page available

10.1093/neuped/wuag026.319 Get It

Abstract Background In children with non-metastatic atypical teratoid/rhabdoid tumor (ATRT), proton therapy is increasingly utilized worldwide due to the radiosensitivity of afflicted young patients. General questions persist, however, surrounding dose and volume of radiotherapy. Methods Between 2009-2024, 39 children from a single institution with non-metastatic intracranial ATRT received focal proton therapy at a median age of 2.4 years (range 0.7-19). Twenty-two patients had supratentorial tumors and 27 had gross/near total resection prior to radiation. Most common chemotherapy regimens were ACNS0333 and SJYC07 (n = 10 each) and Dana-Farber (n = 6). Four patients received consolidative high-dose chemotherapy after radiation. The median radiation dose was 50.4 Gy (range, 50.4-54). The cumulative incidence method assessed freedom from selected endpoints.The Fine-Gray method assessed the level of statistical significance between levels of selected prognostic factors. Results With a median followup of 5.2 years (range 0.5-16.2), the 5-yr overall survival, progression-free survival, and local control was 63%, 64%, and 97%, respectively. Thirteen patients developed isolated leptomeningeal failure as first site of recurrence. Only subtotal resection was significantly associated with local recurrence (100% vs 92%, p < 0.05). Patient age, tumor site, extent of resection, radiation dose, and chemotherapy regimen were otherwise not significantly associated with disease control or survival. Four patients experienced symptomatic radiation necrosis, including 1 death: Three of 4 cases received 54 Gy and consolidative intrathecal methotrexate (n = 2) or high dose ACNS0333 intravenous chemotherapy (n = 1, fatal) after radiation. The other patient received 50.4 Gy and necrosis was immediately preceded by ventriculoperitoneal shunt failure. Six patients developed hearing loss requiring aids. One patient developed radiation-induced meningioma a decade following treatment. Conclusion This represents the largest experience reporting 5-year outcomes following focal radiation in children with non-metastatic intracranial ATRT. When applied with a variety of modern chemotherapy regimens in real-world settings, focal proton therapy at a dose of 50.4 Gy may offer the best therapeutic ratio but does not eliminate serious toxicity. If avoidance of craniospinal radiation remains an ongoing priority, further improvement in survival will depend upon systemic therapy.
14TEAD Inhibition by IAG933 as a Novel Therapeutic Strategy for Cholangiocarcinoma
Nishi, Hidemi , Jessen, Erik , Carlson, Danielle M. , Abdelrahman, Amro M, Ozmert, Enis H, Safi, J Pedro F, Yee, Shelby K, Siegler, Emily L. , Werneburg, Nathan W., Wilbanks, Brandon , Carlson, Danielle Marie , Safi, J. Pedro F., Yee, Shelby K., Sample, Jack W. , Smoot, Rory L.

Mayo Clinic

The Oncologist | June 23, 2026 | Volume: 31 | Issue: Supplement_1 | Pages: No page available

10.1093/oncolo/oyag205.015 Get It

Abstract Background Cholangiocarcinoma (CCA) is an aggressive hepatobiliary malignancy with marked molecular heterogeneity, limited systemic treatment options, and poor prognosis. Chemoresistance and KRAS mutations remain major therapeutic challenges. Dysregulation of the Hippo pathway, particularly YAP/TAZ hyperactivation, drives CCA progression and resistance. TEAD, the essential transcriptional partner of YAP/TAZ, represents a promising target. IAG933 is a novel oral pan-TEAD inhibitor designed to disrupt YAP/TAZ–TEAD interactions. RMC-6236, a pan-KRAS inhibitor, has also gained attention. Combining TEAD and KRAS inhibition may overcome resistance and improve efficacy in CCA. Methods We evaluated IAG933 in human (HuCCT1, RBE) and murine (SB1, FAC) CCA cell lines. Cells were treated with IAG933 alone or in combination with GemCis or RMC-6236. Cell viability assays were used to determine IC50 values and calculate combination index (CI). TEAD activity was assessed by luciferase reporter and qRT-PCR of YAP/TAZ target genes (CTGF, CYR61, NUAK2). In vivo efficacy was evaluated in syngeneic orthotopic and patient-derived xenograft (PDX) models. Results IAG933 suppressed TEAD-dependent transcription (IC50≈500 nM) and downregulated YAP/TAZ target genes. Combination with GemCis or RMC-6236 produced synergistic effects (CI < 1) in all CCA lines. In vivo, IAG933 monotherapy suppressed tumor growth similarly to GemCis. Dual TEAD and KRAS inhibition achieved marked tumor regression and significantly delayed tumor regrowth after treatment cessation in KRAS-mutant PDX models. Conclusion IAG933 effectively suppresses YAP/TAZ–TEAD signaling and inhibits CCA growth. While the combination with GemCis showed limited additional benefit due to strong single-agent efficacy, synergy with RMC-6236 produced durable antitumor effects, particularly in run-out studies, delaying regrowth in KRAS-mutant models. These findings highlight IAG933 as a promising therapeutic candidate targeting the Hippo–TEAD pathway, with potential benefit in KRAS-mutant CCA.
Research through Evaluation for Large Language Model in Patient-Clinician Communications
Holmes, Jason, Hobson, Jared, Bennett, Alexandra, McKone, Elizabeth L. , Ebner, Daniel, Shiraishi, Satomi, Patel, Samir H. , Yu, Nathan Y. , Hallemeier, Chris L., Ball, Brooke E., Waddle, Mark, Liu, Wei, Hao, Yuexing , Holmes, Jason , Routman, David M. , Kalantari, Saleh , Ghassemi, Marzyeh

Mayo Clinic

No container title available | June 18, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-9735115/v1 | PMID 42370275 Get It

Abstract Large Language Models (LLMs) demonstrate strong capabilities in healthcare applications. However, recruiting human evaluators to assess usability and effectiveness becomes challenging in the large-scale LLM-generated outcomes. Existing metrics are often outdated for evaluating LLM-based healthcare technologies. This paper proposes a Research through Evaluation (RtE) approach that can refine metrics and improve assessments of LLM-generated outputs. We deploy RtE in a retrospective comparative study of prostate cancer patient inquiries, comparing responses from human clinical care teams with those generated by a GPT-4-based in-basket bot. Through three rounds of co-evaluations with clinical professionals and an LLM-as-graders study with four LLMs, the RtE method shows that starting with small, iterative evaluations helps human graders adjust metrics to suit their daily practices better. Additionally, in the LLM-as-graders study, LLMs exhibit similar behavior, preferring the in-basket bot's responses over the clinical care team. Our methodology and findings demonstrate that the RtE method can enhance the transparency and robustness of evaluation metrics for LLM-generated content, with the potential to generalize to evaluations in other clinical practices.
Recommendation Statement for the Validation, Implementation, and Clinical Application of Artificial Intelligence Within a Clinical Laboratory from the Digital Pathology Association
Silberman, Nathan , Parwani, Anil, McClintock, David S. , Lujan, Giovanni, Garcia, Christopher, Hanna, Matthew G., Pantanowitz, Liron, Lennerz, Jochen K., SHOWALTER, TIMOTHY, Gerrard, Paul, Parwani, Anil Vasdev , Lujan, Giovanni Mario , Gondim, Dibson , Hanna, Matthew G., Pantanowitz, Liron , Showalter, Timothy N.

Mayo Clinic

AI in Precision Oncology | June 11, 2026 | Volume: 3 | Issue: 4 | Pages: 71-97

10.1177/2993091x261455975 Get It

Background: The rapid adoption of digital pathology and artificial intelligence (AI) in oncology creates multiple opportunities for precision diagnostics but also creates an urgent need for evidence-based standards to ensure safe and effective implementation. Goal: This article, developed by the Digital Pathology Association, presents recommendations for digital pathology as well as the validation and clinical utility of AI-enabled digital pathology tools in clinical practice. This guidance addresses analytical and clinical validation, algorithm reliability, and criteria for establishing clinical utility attributed to test use. Key recommendations emphasize separate validation of scanning processes and AI algorithms, concordance studies to support interscanner generalizability, rigorous assessment of accuracy and reliability in real-world settings, and clear description of algorithmic use limitations. These recommendations further provide frameworks for when AI may replace or augment existing diagnostic approaches, such as biomarker scoring, cancer diagnosis, and prognostic risk assessment. Conclusions: By considering payer, regulatory, and clinical perspectives, the recommendations promote transparency, trust, and reproducibility in digital pathology while encouraging value-based care delivery. We support responsible innovation in computational pathology, ensuring that AI applications achieve not only technical performance goals but also deliver measurable clinical benefit to patients.
PHLPP Signaling Regulates NaV1.8 Innervation in Post-traumatic Osteoarthritis (PTOA) (P7-14.001)
Torres, Haydee, Bradley, Elizabeth, Li, Xiaodong , Zars, Elizabeth, Oviedo, Manuela , Weaver, Samantha, Peralta-Herrera, Eduardo , Peters, Christopher, Staff, Nathan, Westendorf, Jennifer, Torres, Haydee M., Li, Xiaodong, Zars, Elizabeth L. , Weaver, Samantha, Westendorf, Jennifer J.

Mayo Clinic

Neurology | June 10, 2026 | Volume: 106 | Issue: 11_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000217385 Get It

Effectiveness of Infliximab for Refractory Non-ischemic Cerebral Enhancing Foreign-body Granulomatous Lesions Following Endovascular Therapy (P1-1.003)
Taha, Farris, Tagg, Nathan, Smith, Andrew, Flanagan, Eoin , Brown, Robert, Pittock, Sean, Perez-Giraldo, Gina, McKeon, Andrew, Aboseif, Albert , Taha, Farris , Tagg, Nathan T. , Flanagan, Eoin P. , Pittock, Sean J. , Perez-Giraldo, Gina , McKeon, Andrew

Mayo Clinic

Neurology | June 10, 2026 | Volume: 106 | Issue: 11_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000215791 Get It

Therapeutic Outcomes in VEXAS Syndrome: A Multicenter Comparative Cohort of Allogeneic Hematopoietic Stem Cell Transplantation and Hypomethylating Agents
Fathima, Saubia, Wong, Margaret Mei‐Kay, Gonzalez-Lugo, Jesus, Geyer, Susan M. , Alsugair, Ali, Langer, Kimberly J., Lasho, Terra L. , Finke, Christy, Choi, Jun, Abdul‐Hay, Maher, Ho, Gary , Litzow, M. R., Matin, Aasiya , Hefazi, M., Shah, Mithun V., Al-Kali, Aref, Begna, Kebede H. , Gangat, Naseema , Saliba, A., Kewan, Tariq, Bartoo, Gabriel, Kutzke, Jade, McCullough, Kristen, Sullivan, Megan, Reichard, Kaaren K., Olteanu, Horatiu , Kusne, Yael , Palmer, Jeanne, Punwani, Nathan , Riwes, Mary, Krakow, Elizabeth F., Langston, Amelia , Kourelis, Taxiarchis, Foran, James M. , Patnaik, Mrinal M., Beck, David B. , Mangaonkar, Abhishek A. , Krakow, Elizabeth F. , Riwes, Mary , Alsugair, Ali , Lasho, Terra L , Ho, Gary , Durani, Urshila , Hogan, William J , Gangat, Naseema , Saliba, Antoine N , Go, Ronald S , Warrington, Kenneth J , Olteanu, Horatiu , Murthy, Hemant S , Badar, Talha , Kusne, Yael N , Chhabra, Saurabh , Langston, Amelia , Foran, James M , Koster, Matthew J , Beck, David B , Alkhateeb, Hassan B , Fathima, Saubia , Gonzalez‐Lugo, Jesus D. , Geyer, Susan , Sirenko, Maria , Finke, Christy M. , Abdul‐Hay, Maher , Litzow, Mark R. , Durani, Urshila , Hefazi, Mehrdad , Hogan, William J. , Shah, Mithun V., Al‐Kali, Aref , Saliba, Antoine N. , Go, Ronald S. , Bartoo, Gabriel , Kutzke, Jade L. , McCullough, Kristen , Warrington, Kenneth J. , Sullivan, Megan M. , Reichard, Kaaren K. , Murthy, Hemant S. , Badar, Talha , Palmer, Jeanne , Chhabra, Saurabh , McGuirk, Joseph P. , Kourelis, Taxiarchis , Dingli, David , Koster, Matthew J. , Patnaik, Mrinal M. , Alkhateeb, Hassan B. , Mangaonkar, Abhishek A.

Mayo Clinic

American Journal of Hematology | June 9, 2026 | Volume: 101 | Issue: 9 | Pages: 2166-2176

10.1002/ajh.70401 | PMID 42260942 Get It

ABSTRACT Hypomethylating agents (HMA) and allogeneic hematopoietic stem cell transplantation (alloHSCT) have both demonstrated remissions in VEXAS; however, comparative data is lacking. We conducted a multicenter, retrospective analysis of 66 patients diagnosed with VEXAS syndrome treated with HMA ( n = 35) or alloHSCT ( n = 31). Baseline characteristics such as genetics, co‐morbidities, and performance status were balanced between the groups, except older age in the HMA group. Median follow‐up from therapy initiation was 18 months (95% CI: 11–26), and 14 (21%) deaths were reported (alloHSCT n = 3; HMA n = 11). Among all evaluable patients within the alloHSCT cohort, all patients achieved molecular remission, and a substantial proportion of patients discontinued glucocorticoids (58%). In contrast, HMA therapy was associated with lower but meaningful rates of molecular remission (22%) and glucocorticoid discontinuation (6%). In a real‐world setting, HMA therapy was associated with a high discontinuation rate related to toxicity or lack of response. On multivariable analysis adjusted for age and Charlson Comorbidity Index, alloHSCT was associated with improved overall survival (HR = 0.20, 95% CI: 0.05–0.81; p = 0.024). This association remained consistent across multiple ancillary sensitivity analyses, including restriction to transplant‐eligible patients, patients aged ≤ 75 years, 1:1 matching, and propensity score‐based weighted analyses. Although limited by retrospective design, these findings suggest that alloHSCT remains an attractive and potentially curative strategy in selected patients with VEXAS. Prospective validation of these findings is warranted.
PET Imaging of Osteomyelitis with [68Ga]Ga-BP
Pandey, Mukesh K., Bansal, Aditya, Sharma, Shalini, Karau, Melissa J. , Raval, Yash S. , Broski, S. M., Patel, Robin , Nathan, Mark, Lowe, Val J., Pandey, Mukesh K. , Broski, Stephen M. , Patel, Robin , Broski, Stephen M , Pandey, Mukesh K , Raval, Yash S. , Bansal, Aditya , Lowe, Val J. , Karau, Melissa

Mayo Clinic

Chemical & Biomedical Imaging | June 9, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1021/cbmi.6c00082 | PMID 42953237 Get It

Abstract A low-cost, easy-to-adopt noninvasive imaging modality for differentiating bacterial infection from inflammation is desirable to accurately diagnose bacterial infections. Herein, a bacteria-specific PET probe, [68Ga]Ga-BP, was developed and evaluated in rat models of foreign body-associated osteomyelitis induced by methicillin-resistant Staphylococcus aureus, Pseudomonas aeruginosa, and Klebsiella pneumoniae and was directly compared with sterile inflammation and uninstrumented uninfected controls. [68Ga]Ga-BP-based imaging of MRSA-infected tibiae was also compared to [68Ga]Ga-citrate and [18F]FDG. After iron depletion, dynamic PET/CT imaging was performed at 15–120 min postinjection of radiotracers, followed by assessment of ex vivo biodistribution. [68Ga]Ga-BP successfully detected tibial infection and demonstrated >6-fold higher uptake in infected tibiae with all three bacterial species versus contralateral tibiae via PET imaging. [68Ga]Ga-BP outperformed [68Ga]Ga-citrate and [18F]FDG in identifying MRSA infection. [68Ga]Ga-BP represents a promising, noninvasive PET imaging agent for direct bacterial detection and bacterial infection treatment monitoring.
Mirikizumab Demonstrates Long-Term Efficacy on Histological Resolution in the Phase 3, Multicenter, Open-Label VIVID-2 Extension Study
Reinisch, W, Jairath, V, Protic, M, Hertogh, G De, Harpaz, N, Hisamatsu, T, D'Haens, G, Pai, R, Morris, N, Hozak, R, Yu, G, Durand, F, Magro, F, Reinisch, W, Protić, Marijana , Hertogh, G De, Harpaz, Noam , Hisamatsu, Tadakazu, D’Haens, Geert , Pai, Rish, Morris, Nathan , Hozak, Rebecca R., Durand, Frédérick

Mayo Clinic

Zeitschrift für Gastroenterologie | June 8, 2026 | Volume: 64 | Issue: 05 | Pages: e139-e140

10.1055/s-0046-1823082 Get It